Every 10-Q that VASO CORPORATION (VASO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VASO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VASO filings page.
Vaso Corporation reported modestly higher revenue from continuing operations and a smaller overall loss for the six months ended June 30, 2026, while continuing to exit its IT services businesses. Revenue from continuing operations was $11.2 million in the quarter and $21.0 million year-to-date, up 8% and 3% from 2025, driven mainly by higher GE Healthcare (GEHC) diagnostic imaging equipment deliveries in the professional sales services segment and stronger equipment sales in China.
Gross margin from continuing operations remained high at 79% in the quarter. Quarterly operating income from continuing operations improved to $974,000, and net income from continuing operations was $840,000, versus $323,000 a year earlier. For the first half, Vaso had a small net income from continuing operations of $115,000, but a total net loss of $343,000 including discontinued operations, an improvement from a $1.3 million loss in 2025.
The IT segment is now presented as discontinued operations after the sale of VasoHealthcare IT in November 2025 and the agreement to sell NetWolves for $14.5 million in cash, signed July 31, 2026. Discontinued operations generated a net loss of $458,000 in the first half. Vaso ended June 30, 2026 with $38.3 million in cash and cash equivalents and working capital of $22.3 million. Deferred commission revenue reached $41.5 million, reflecting strong order bookings under the long-term GEHC sales representation agreement, which runs through 2030. GEHC accounted for 94% of total revenue and a large share of receivables, highlighting significant customer concentration.
Vaso Corporation reported essentially flat results for the quarter ended March 31, 2026, with revenue of $19.4 million versus $19.5 million a year earlier and a net loss of $0.9 million, slightly improved from a $1.1 million loss. Gross margin ticked up to 60%.
Professional sales service revenue rose 6% to $9.2 million, equipment revenue grew 27% to $0.6 million, and IT revenue fell 7% to $9.6 million, partly reflecting the prior VasoHealthcare IT divestiture. Cash declined to $22.0 million from $35.1 million after a $12.6 million operating cash outflow driven mainly by higher receivables and lower accrued liabilities. Deferred commission revenue reached $39.5 million, and total remaining performance obligations were about $103 million, highlighting a sizable contracted backlog, while GEHC accounted for 48% of quarterly revenue.
Vaso Corporation reported stronger Q3 results. Revenue rose to $22.657 million (up 9% year over year), driven by higher commissions in professional sales services and steady IT performance. Gross profit increased to $13.896 million (61% margin). Operating income was $1.538 million versus a loss last year, and net income reached $1.711 million (from a prior loss), reflecting higher segment gross profit and the absence of prior-year transaction costs.
The IT segment delivered $11.218 million with 87% recurring revenue; professional sales services generated $10.820 million; equipment contributed $0.619 million. Adjusted EBITDA improved to $1.617 million from a loss. Cash and cash equivalents were $34.859 million, supported by $9.012 million operating cash flow year-to-date. Deferred revenue stood at $39.412 million (including $21.854 million long term), and remaining performance obligations totaled $109.8 million. GE Healthcare represented 48% of Q3 revenue; total working capital was $20.308 million.